BioXcel Therapeutics (BTAI) Net Shares Issued and Repurchased (2017 - 2026)
BioXcel Therapeutics (BTAI) posted Net Shares Issued and Repurchased of $119000.0 for Q1 2026, up 52.56% on a QoQ basis from $78000.0 in Q4 2025, and up 58.67% year-over-year from $75000.0 in Q1 2025.
Powered by 
Analysis
BioXcel Therapeutics (BTAI) Net Shares Issued and Repurchased (2017 - 2026) Analysis & Trends
BioXcel Therapeutics has reported Net Shares Issued and Repurchased for 10 years, with the latest figure at $119000.0 in Q1 2026.
- On a quarterly basis, Net Shares Issued and Repurchased rose 58.67% year-over-year to $119000.0 in Q1 2026; TTM through Mar 2026 was $119000.0, a 58.67% increase from a year earlier, with the FY2025 full-year figure at $78000.0, up 95.0% from the prior year.
- Net Shares Issued and Repurchased was $119000.0 for Q1 2026 at BioXcel Therapeutics, up from $78000.0 in the prior quarter.
- The five-year high for Net Shares Issued and Repurchased was $1.4 million in Q4 2022, with the low at $21000.0 in Q1 2024.
- Average Net Shares Issued and Repurchased over 5 years is $511000.0, with a median of $119000.0 recorded in 2026.
- The sharpest annual moves came in 2024 and 2025: Net Shares Issued and Repurchased plunged 97.81% in 2024, then jumped 257.14% in 2025.
- Over 5 years, Net Shares Issued and Repurchased stood at $1.4 million in 2022, then slipped by 20.9% to $1.1 million in 2023, then sank by 96.33% to $40000.0 in 2024, then soared by 95.0% to $78000.0 in 2025, then jumped by 52.56% to $119000.0 in 2026.
- The last three Net Shares Issued and Repurchased figures came in at $119000.0 (Q1 2026), $78000.0 (Q4 2025), and $75000.0 (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.04 Bn | 198.05 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.35 Bn | 178.17 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.94 Bn | 74.94 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.53 Bn | 56.34 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.25 Bn | 49.11 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.41 Bn | 31.10 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.19 Bn | 29.91 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | - |
| 10 | BioXcel Therapeutics | 2.19 Mn | 2.19 Mn | 160,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 119,000.00 |
| Dec 31, 2025 | 78,000.00 |
| Mar 31, 2025 | 75,000.00 |
| Dec 31, 2024 | 40,000.00 |
| Mar 31, 2024 | 21,000.00 |
| Dec 31, 2023 | 1.09 Mn |
| Mar 31, 2023 | 958,000.00 |
| Dec 31, 2022 | 1.38 Mn |
| Mar 31, 2022 | 840,000.00 |
| Dec 31, 2021 | 869,000.00 |
| Mar 31, 2021 | 505,000.00 |
| Dec 31, 2020 | 1.15 Mn |
| Mar 31, 2020 | 100,000.00 |
| Dec 31, 2019 | 384,800.00 |
| Mar 31, 2019 | 70,000.00 |
| Dec 31, 2018 | 400,648.00 |
| Sep 30, 2018 | 120,000.00 |
| Jun 30, 2018 | 154,178.00 |
| Mar 31, 2018 | 143,148.00 |
| Dec 31, 2017 | 1.81 Mn |